Welcome to our dedicated page for Allarity Therapeutics SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allarity Therapeutics, Inc. SEC filings document the company’s clinical-stage oncology business, capital structure, governance, and material-event disclosures. The filings identify Allarity’s Nasdaq-listed common stock and emerging growth company status, and include 8-K reports covering Regulation FD presentations, scientific and clinical updates for stenoparib and the DRP® companion diagnostic, intellectual-property developments, operating and financial results, and promissory-note financing.
Proxy materials describe annual meeting matters and stockholder voting procedures, while material definitive agreement filings and other current reports provide formal disclosure on financing arrangements, corporate progress, and regulatory or clinical communications tied to Allarity’s precision oncology programs.
Allarity Therapeutics, Inc. has entered a common stock purchase agreement with Tumim Stone Capital that allows the company, at its discretion, to sell up to $6.0 million of common stock over 24 months. Under Nasdaq’s 19.99% exchange cap, this prospectus supplement registers 3,214,588 shares for resale by Tumim.
Sales prices will be based on a discount to volume-weighted average trading prices, so the actual number of shares issued will vary with the stock price. As of January 27, 2026, Allarity had 16,080,980 shares outstanding and a public float of approximately $20.1 million.
The company warns that issuing shares to Tumim and Tumim’s subsequent resales could significantly dilute existing stockholders and pressure the share price. Any proceeds Allarity receives from selling shares to Tumim are expected to be used for working capital and general corporate purposes, including potential debt repayment and operating expenses.
Allarity Therapeutics, Inc. entered into a Common Stock Purchase Agreement with Tumim Stone Capital, creating an equity line of credit that allows the company, at its sole discretion, to sell up to $6,000,000 of newly issued common shares over time.
Shares sold under the agreement will be priced at a discount to market, equal to either 95% of the lowest one-day volume‑weighted average price or 97% of the lowest three‑day volume‑weighted average price, subject to volume and dollar limits per draw of up to $1,000,000 or $2,000,000.
The investor cannot exceed 4.99% ownership of outstanding common stock, or 9.99% if it elects that higher cap. Issuances are also limited by an Exchange Cap tied to 19.99% of pre‑agreement shares outstanding, unless stockholders later approve a waiver and, if needed, an increase in authorized shares. Allarity paid a $45,000 commitment fee for this financing flexibility.
Allarity Therapeutics, Inc. reported an equity award to senior executive Jeremy R. Graff, its President and Chief Development Officer. On January 7, 2026, Graff received 133,333 shares of common stock in the form of restricted stock units at a price of $0 per share under the company’s Amended and Restated 2021 Equity Incentive Plan. These RSUs will vest in three equal one-third installments on the first, second, and third anniversaries of the grant date, conditioned on his continued relationship with the company. Following this award, Graff beneficially owns 381,644 shares of Allarity Therapeutics common stock, held directly.
Allarity Therapeutics (ALLR) filed its Q3 2025 report, highlighting a smaller quarterly net loss and stable liquidity. Net loss was $2.8 million for the quarter and $7.9 million year-to-date. Cash and cash equivalents were $16.9 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months.
Operating cash outflow was $11.6 million for the nine months. The company raised capital via an ATM program with $9.7 million net proceeds year-to-date and completed a private placement of 1,562,500 shares at $1.60 per share for roughly $2.5 million gross. Allarity also executed a share repurchase program, buying 2,600,763 shares for $2.706 million, with $2.294 million remaining authorized.
The FDA granted Fast Track designation to stenoparib for advanced ovarian cancer, supporting development interactions. The company reported a material weakness in internal controls related to accounting for the repurchase program and is implementing remediation. Shares outstanding were 16,111,461 as of September 30, 2025; 15,811,886 were reported outstanding as of November 13, 2025.
Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc. (ALLR), reported transactions dated 09/30/2025. 39,494 restricted stock units vested and were reported as acquired, and 14,613 shares were disposed of at $1.58 per share, leaving 24,881 shares owned directly after the transactions. The filing also shows 223,430 restricted stock units/derivative securities beneficially owned following the reported transactions. The RSUs convert one-for-one to common stock and stem from grants of 118,483 RSUs on 09/30/2024 and 144,441 RSUs on 01/22/2025, each vesting in three equal annual installments beginning on the first anniversary of the respective grant dates.
Allarity Therapeutics, Inc. filed an S-3 shelf registration describing an offering that includes 760,916 shares of Common Stock and 801,584 Pre-Funded Warrants exercisable for Common Stock at an exercise price of $0.0001 per share. The company’s authorized capital structure includes 250,000,000 shares of Common Stock and 500,000 shares of undesignated preferred stock. The prospectus enumerates the distribution methods permitted under the plan, including ordinary brokerage transactions, block trades, principal purchases and exchange distributions. The document lists estimated offering expenses including $20,000 for accounting fees and $50,000 for legal fees. A table of exhibits identifies corporate charter amendments, bylaws, a specimen stock certificate, forms of pre-funded warrant, a securities purchase agreement and a registration rights agreement dated September 22, 2025. The filing is signed by the CEO, CFO and multiple directors with signatures dated September 25, 2025.
Allarity Therapeutics, Inc. reported that Dr. Jeremy Graff, its President and Chief Development Officer, presented new and updated clinical data from the company’s ongoing Phase 2 trial in advanced ovarian cancer. The presentation took place at the American Association for Cancer Research 7th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025, at the Grand Hyatt Denver in Denver, Colorado.
The company also noted that a press release dated September 22, 2025, containing further details on the Phase 2 trial update has been issued and is included as an exhibit.
Allarity Therapeutics, Inc. filed a Form 8-K reporting a material event dated September 22, 2025. The filing lists two material agreements as exhibits: a Form of Securities Purchase Agreement and a Form of Registration Rights Agreement, each dated September 22, 2025, described as between the company and an investor. The document identifies the company's common stock ticker as ALLR on The Nasdaq Stock Market LLC and is signed by Thomas H. Jensen, Chief Executive Officer. The filing includes an Inline XBRL cover page reference but does not disclose financial terms, investor identity, or the size or economic impact of the transaction.
Allarity Therapeutics, Inc. reported that its CEO, Thomas Jensen, has been invited to present at the Biomarkers & Precision Medicine 2025 conference in London, organized by Oxford Global. The company also furnished a related press release as an exhibit, providing additional details on this conference participation.
Allarity Therapeutics, Inc. reported that the U.S. Food and Drug Administration has granted Fast Track designation to stenoparib, its investigational treatment for patients with advanced ovarian cancer. The company disclosed that this development was announced in a press release dated August 26, 2025, which is included as an exhibit to the report.